Minimally Invasive Glaucoma Surgery (MIGS) Devices Market To Witness 24.9% CAGR Growth Through 2030: Key Industry Drivers
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The minimally invasive glaucoma surgery (migs) devices market size has experienced substantial growth in recent years. It is projected to expand from $0.89 billion in 2025 to $1.14 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 28.1%. Factors contributing to this historical growth include the rising prevalence of glaucoma, an expanding aging demographic, the inherent limitations of traditional glaucoma surgeries, increasing awareness regarding vision preservation, and the growing adoption of cataract procedures.
The minimally invasive glaucoma surgery (migs) devices market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $2.79 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 24.9%. This expansion during the forecast period can be primarily attributed to an increasing number of glaucoma patients, greater acceptance of less invasive surgical choices, a rising need for outpatient eye procedures, a heightened emphasis on improved quality-of-life results, and broadened availability of specialized eye care clinics. Key developments during this period include a surge in the adoption of minimally invasive glaucoma interventions, a growing inclination towards MIGS for early and moderate stages of glaucoma, increased application of MIGS alongside cataract operations, the proliferation of outpatient and ambulatory glaucoma surgeries, and a heightened desire for glaucoma treatments that are both safer and facilitate quicker recovery.
Get A Free Sample Report With In-Depth Market Insights:
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Growth Backed By Core Demand Fundamentals
The future expansion of the minimally invasive glaucoma surgery (MIGS) devices market is anticipated due to the rising occurrence of eye disorders. These disorders encompass diverse conditions impacting sight and the eyes, with their increasing prevalence attributed to shifts in lifestyle, environmental factors, and an aging global demographic. Minimally invasive glaucoma surgery (MIGS) devices represent advanced instruments employed in treating various ocular ailments, principally aimed at lowering intraocular pressure (IOP) to halt or manage glaucoma’s progression. A notable example cited in 2024 by the National Eye Institute, a US-based government agency, indicates that around 2.2 million Americans will be blind or partially blind by 2030. Consequently, the growing frequency of eye disorders is a key force behind the minimally invasive glaucoma surgery (MIGS) devices market.
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Segment Landscape: Which Areas Lead Development?
The minimally invasive glaucoma surgery (migs) devices market covered in this report is segmented –
1) By Product Type: Trabecular Micro-Stents, Subconjunctival Micro-Shunts, Suprachoroidal Stents, Canaloplasty & Schlemm’s Canal Devices
2) By Surgical Approach: MIGS in Conjunction with Cataract Surgery, Stand-Alone MIGS Procedures
3) By Target Anatomical Pathway: Trabecular Meshwork, Schlemm’s Canal, Suprachoroidal Space, Subconjunctival Space
4) By Procedure Type: Ab-Interno MIGS, Ab-Externo MIGS
5) By End User: Ophthalmology Clinics, Ambulatory Surgery Centers (ASCs), Specialized Eye Hospitals
Subsegments:
1) By Trabecular Micro-Stents: Single-Lumen Trabecular Micro-Stents, Multi-Lumen Trabecular Micro-Stents, Scaffold-Based Trabecular Stents, Drug-Eluting Trabecular Micro-Stents
2) By Subconjunctival Micro-Shunts: Gel-Based Micro-Shunts, Polymer-Based Micro-Shunts, Collagen-Based Micro-Shunts, Fixed-Lumen Subconjunctival Micro-Shunts
3) By Suprachoroidal Stents: Passive Suprachoroidal Stents, Flow-Regulated Suprachoroidal Stents, Biocompatible Polymer Suprachoroidal Stents
4) By Canaloplasty & Schlemm’s Canal Devices: Microcatheter-Based Canaloplasty Devices, Viscodilation & Schlemm’s Canal Expanders, Implant-Free Canaloplasty Systems, Schlemm’s Canal Scaffolding Devices
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Growth Trends Reshaping The Competitive Landscape
Leading companies within the minimally invasive glaucoma surgery (MIGS) devices market are prioritizing the development of sophisticated solutions, such as sustained-release drug-delivery implants, designed to supersede conventional topical glaucoma therapies. A sustained-release implant functions as a device that continually administers medication over time, consequently boosting patient adherence, decreasing the frequency of dosing, and elevating treatment effectiveness. For example, in February 2024, Celanese Corporation, a US-based specialty materials company, formed a partnership with Glaukos to commercially introduce the iDose® TR (Travoprost Intracameral Implant), leveraging Celanese’s VitalDose® Ethylene Vinyl Acetate (EVA) platform. This innovative product substitutes traditional eye-drop regimens by providing ongoing intraocular delivery of travoprost directly into the eye for several months. Integrated within Glaukos’ MIGS portfolio, it furnishes a minimally invasive therapeutic alternative that diminishes the requirement for daily eye drops, improves patient compliance, and supports consistent intraocular pressure regulation, ultimately improving long-term treatment outcomes.
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the minimally invasive glaucoma surgery (migs) devices market are Glaukos Corporation, Sight Sciences Inc., Alcon Inc., Johnson & Johnson Vision Care Inc., Bausch & Lomb Incorporated, Carl Zeiss Meditec AG, Nova Eye Medical Limited, iSTAR Medical SA, New World Medical Inc., MicroSurgical Technology Inc., ASICO LLC, Ziemer Ophthalmic Systems AG, Ellex Medical Lasers Ltd., Lumenis Ltd., Iridex Corporation, Katena Products Inc., Oertli Instrumente AG, Sifi S.p.A., Aquesys Inc., Beaver‑Visitec International
View The Full Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report:
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the minimally invasive glaucoma surgery (MIGS) devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimally invasive glaucoma surgery (migs) devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
